Commercial Prospects of Drug Delivery Technologies Analysed by Visiongain

12 Mar 2012 • by Natalie Aster

This decade, many commercial opportunities for improved drug delivery exist. Technologies and applications giving improved clinical efficacy, patient convenience and treatment compliance will achieve success. Drug delivery R&D is promising. Suppliers and users of the technology will benefit.

Drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs. Biologicals and vaccines will profit especially.

In particular, new Visiongain's report ”Drug Delivery Technologies: Commercial Prospects 2012-2022” forecasts six submarkets to 2022, showing potential revenues for:

  • Oral delivery 
  • Inhaled delivery 
  • Transdermal delivery 
  • Ocular delivery 
  • Nasal delivery 
  • Implants for drug delivery.

The study discusses 3M, Catalent, Alkermes, Generex Biotechnology, pSivida and many other technology providers, letting to assess outlooks for the industry and market.

Report Details:

Drug Delivery Technologies: Commercial Prospects 2012-2022
Published: January, 2012
Pages: 167
Price: US$ 2.642,00

In analysis, the drug delivery technology industry will achieve high revenue growth from 2012 to 2022. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.

Visiongain's study provides data, analysis and opinion aiming to benefit research, calculations and presentations.

More information can be found in the report “Drug Delivery Technologies: Commercial Prospects 2012-2022” by Visiongain.

To order the report or ask for sample pages contact


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970